Agilent Technologies Inc. (NYSE:A) today introduced the SureSelect Clinical Research Exome. The performance-optimized exome design was developed in collaboration with researchers from Emory University and the Children’s Hospital of Philadelphia.
SureSelect Human All Exon V5 was used as the core for the new design. Performance has been enhanced in disease-associated regions, providing 10 percent deeper coverage within these targets from only 4Gb of sequencing, while maintaining excellent coverage in other exome regions.
“Our goal was to create a comprehensive exome design that provides higher coverage in regions that are associated with human disease,” said Maduri Hedge, professor of Human Genetics at Emory University. “Agilent’s ability to enhance current targets and add custom content to the Human All Exon V5 provided an ideal solution to help us achieve this.”
The disease-relevant regions in the clinical research exome consist of gene targets commonly associated with, or known to cause, disease, including targets identified in OMIM, HGMD and NCBI’s ClinVar databases. Additional ancestry- and identity-informative content has also been included to facilitate sample tracking. Custom content can be added to the Clinical Research Exome using SureDesign, a free online design tool for SureSelect. The Clinical Research Exome targets approximately 54Mb of content and is optimized for coverage uniformity, enabling proportional performance improvement as sequencing allocation per library is increased. The SureSelect Clinical Research Exome can be paired with existing SureSelect kits to provide significantly reduced hybridization times—as little as 90 minutes—and provide sequencing-ready libraries in just one day.“We are pleased to share this exceptional sequencing tool with the research community,” said Victor Fung, senior director of Marketing for Agilent’s Diagnostics and Genomics Solutions business. “It is unmatched in its ability to provide superior coverage, uniformity and efficiency in key regions, enabling up to two-and-a-half times greater sample throughput than any other exome available today.”
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV